Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751634 | 0.87 | GRM5 (0.35) | GRM5HTR2CHTR2ATP53MAPT | |
| SCHEMBL5751918 | 0.83 | MAPT (0.37) | GRM5HTR2CHTR2ATP53MAPT | |
| SCHEMBL5750618 | 0.79 | HRH4 (0.35) | GRM5HTR2CHTR2AMEN1KMT2A | |
| SCHEMBL13906840 | 0.79 | GRM5 (0.36) | GRM5HTR2CHTR2ACHRM4MEN1 | |
| SCHEMBL4718820 | 0.75 | — | — | |
| SCHEMBL408899 | 0.71 | GLA (0.33) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL81282 | 0.70 | TSHR (0.41) | MAPTKMT2ASMN1; SMN2LMNA | |
| SCHEMBL5250886 | 0.68 | GRM5 (0.34) | GRM5SMN1; SMN2HTT | |
| SCHEMBL9607522 | 0.68 | MAPK1 (0.34) | GRM5 | |
| SCHEMBL4639035 | 0.67 | GRM5 (0.34) | GRM5SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160811-A1 | Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1648890-A2 | ARYL-CONDENSED 3-ARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010000-A2 | ARYL-CONDENSED 3-ARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160811-A1 | Aryl-condensed 3-arylpridine compounds and use thereof for controlling pathogenic fungi | CBR3, C1R, CBR1 | GRM5 987/4885HTR2C 1466/4885HTR2A 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.